Neoplasms Clinical Trial
— DICODOMOfficial title:
Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks
NCT number | NCT03336489 |
Other study ID # | HPD_2016_24 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 29, 2017 |
Est. completion date | November 7, 2018 |
Verified date | November 2017 |
Source | Fondation Ophtalmologique Adolphe de Rothschild |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In Paris, France, home hospice care for terminally ill patients is organized by four
"palliative care networks". These networks are responsible for information sharing and
coordination of all health care professionals working with the patient. Two different systems
are in place to ensure continuity of care outside working hours, in such a setting. In the
first system, palliative care specialists from the network are reachable over the phone 24/7
by the patient or its caregivers, whenever needed. In the second system, medical information
about the patient, regularly updated by the network's medical team, is available to
professionals via a secure website, so that in case the patient requires an urgent medical
home visit outside working hours, the visiting physician has access to accurate information.
The study's goal is to compare patient's and caregiver's satisfaction between these two
systems of continuity of care.
For that purpose, patients will be taken care of as usual by every palliative care network.
In every instance where the patient or caregivers have reached out for medical help through
the network's continuity of care system, the patient or caregiver will be called 5 days later
by the investigation team to go through a satisfaction questionnaire (Likert scales)
Status | Completed |
Enrollment | 200 |
Est. completion date | November 7, 2018 |
Est. primary completion date | June 20, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient has a disease with fatal prognosis and requires palliative care - Patient lives in Paris, France - Patient benefits from home hospice care through one of the four official Paris palliative care networks Exclusion Criteria: - Pregnant women - Breastfeeding womed - Altered cognitive function with a Mini Mental Status below 20 - Patient not able to communicate or not speaking French - Patient legally not capable of giving informed consent |
Country | Name | City | State |
---|---|---|---|
France | Reseau ENSEMBLE | Paris | |
France | Reseau QUIETUDE | Paris | |
France | Reseaux ParisOuest | Paris | |
France | Reseaux ROPE | Paris |
Lead Sponsor | Collaborator |
---|---|
Fondation Ophtalmologique Adolphe de Rothschild |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Satisfaction about the response given by the network's continuity of care system | Patient's (or caregiver's) satisfaction about the response given by the network's continuity of care system, after the patient or caregiver activated this system at night time or during week-ends or bank holliday, as measured on a 4-level Likert scale (verbal questionnaire by phone call) | between the first and tenth day after the patient or caregiver activated the network's continuity of care system |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |